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Simple Summary: Glioblastoma (GBM) is one of the greatest challenges facing neuro-oncology today.
Current treatments are far from satisfactory and, given the poor prognosis of the disease, therapeutic
efforts are focused on palliative management rather than curative intervention. Here, we review the
cellular heterogeneity of GBM, including tumor cells and microglia/macrophages among others, as
well as the genetic, epigenetic and metabolic alterations controlling its initiation and progression.
Then, we describe the genetic and xenotransplantation zebrafish models established in the last few
years for the study of GBM physiopathology and for testing new drugs to improve the treatment of
the disease. Taking this information into account, forthcoming studies using zebrafish models of GBM
are expected to shed light on better diagnosis and treatments, thus providing hope for GBM patients.
Abstract: Glioblastoma (GBM) is the most common of all brain malignant tumors; it displays a
median survival of 14.6 months with current complete standard treatment. High heterogeneity, ag-
gressive and invasive behavior, the impossibility of completing tumor resection, limitations for drug
administration and therapeutic resistance to current treatments are the main problems presented by
this pathology. In recent years, our knowledge of GBM physiopathology has advanced significantly,
generating relevant information on the cellular heterogeneity of GBM tumors, including cancer and
immune cells such as macrophages/microglia, genetic, epigenetic and metabolic alterations, compris-
ing changes in miRNA expression. In this scenario, the zebrafish has arisen as a promising animal
model to progress further due to its unique characteristics, such as transparency, ease of genetic
manipulation, ethical and economic advantages and also conservation of the major brain regions
and blood–brain–barrier (BBB) which are similar to a human structure. A few papers described in
this review, using genetic and xenotransplantation zebrafish models have been used to study GBM
as well as to test the anti-tumoral efficacy of new drugs, their ability to interact with target cells,
modulate the tumor microenvironment, cross the BBB and/or their toxicity. Prospective studies
following these lines of research may lead to a better diagnosis, prognosis and treatment of patients
with GBM.
Keywords: glioblastoma; cancer; tumor microenvironment; glioma-associated microglia/macrophages;
genetics; metabolism; miRNA; zebrafish; drug discovery
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1. Introduction
Glioblastoma (GBM) is one of the greatest challenges facing neuro-oncology today.
This disease represents the most common of all brain malignant tumors, comprising more
than 50% of existing high-grade gliomas. GBM has an annual global incidence of 3–5 cases
per 100,000 inhabitants and a slight predominance in males. This incurable malignant
tumor, with almost non-existent long-term survivors, can occur at any age but presents a
clear peak with the highest incidence in the sixth decade of life [1,2].
Most GBM arise de novo, while secondary GBM tumors commonly develop from
lower grade gliomas [1]. The complexity of managing GBM patients depends on many
factors, including tumor size and location, age, the Karnofsky Performance Scale Index,
tumor histology and the status of molecular markers. The diagnosis of GBM is based on
histological techniques, with a high-grade glioma being defined by atypia, cellular pleo-
morphism, mitosis, vascular proliferation and necrosis, according to the criteria established
by the World Health Organization (WHO) classification. By definition, GBM corresponds to
a grade IV and has the worst prognosis among infiltrating gliomas [3]. In clinical practice,
isocytrate dehydrogenase (IDH) mutations and methylation of the promoter O(6)-methyl
guanine methyl transferase (MGMT) gene are routinely evaluated to improve diagnosis
and the classification of tumors and to estimate the sensitivity of the tumor to alkylating
agents such as temozolomide (TMZ) [4,5]. Despite this, the aggressive and invasive devel-
opment and growth of brain tumors, the impossibility of completing tumor resection, the
limitations for drug administration and therapeutic resistance to treatment are the main
problems presented by this pathology. While overall survival after surgical resection of
the tumor is 3 to 6 months, the inclusion of radiotherapy in the treatment plan increases
this parameter to 12.1 months (2-year survival of 10.4%) and a slight increase in survival to
14.6 months (2-year survival 26.5%) can be achieved by the addition of concomitant and
adjuvant chemotherapy with TMZ. In addition, current treatments are far from satisfactory
and, given the poor prognosis of the disease, therapeutic efforts are mainly focused on
palliative management rather than curative intervention.
In this scenario, different promising lines of research have been initiated for the de-
velopment of new therapeutic strategies to treat GBM [2]. From a cellular and molecular
point of view, GBM tumors present high heterogeneity [6–9], which contributes to their
recurrence and therapeutic resistance [10,11]. In addition, understanding the tumor mi-
croenvironment (TME), the cellular origin and the molecular alterations of the tumor cells
and immune related cells will potentially help to improve the diagnosis, prognosis and
treatment of the disease.
The zebrafish (Danio rerio) has become a well-established model for studying the
physiopathological features and screening of new treatments for several human diseases,
including cancer. Rapid embryo development, its small size and its transparency, genetic
and physiological conservation and ethical and economic advantages have made zebrafish
stand out from all other in vivo models [12]. Concerning GBM, the simplicity to perform
genetic manipulations and the transplantation of human tumor cells, together with the
conservation of the major brain subdivisions in this species, enables researchers to reca-
pitulate the characteristics of human tumors and their related TMEs, in turn, allowing the
mechanism of action of new therapeutic strategies to be evaluated [13].
In this manuscript, we review the physiopathology of GBM from a cellular and
molecular perspective, with a particular focus on macrophages/microglia in the TME,
genetic, epigenetic and metabolic alterations and possibilities for their intervention by
microRNA (miRNA) manipulation. Then, we provide our view on the opportunities and
challenges of zebrafish models for improving our understanding of the disease and the
evaluation of new treatments.
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2. Cellular Pathology and Tumor Microenvironment in Glioblastoma:
Macrophages/Microglia
It is desirable to understand the cellular origin of the disease and the composition
of the TME to establish an early diagnosis, identify therapeutic targets and improve its
outcome. The genomic, epigenomic and transcriptomic characterization of GBMs has
provided information which allowed to establish the different tumor subtypes: proneural,
mesenchymal and classical [14–19]. Aberrations in the expression of platelet-derived
growth factor receptor alpha (PDGFRA), neurofibromatosis type I (NF1) and epidermal
growth factor receptor (EGFR) were associated with the proneural, mesenchymal and
classical subtypes, respectively [19]. However, these mutations can co-exist within a single
tumor, both at the regional and single-cell levels, thus, in this case the designated subtypes
reflect the dominant transcriptional program of a specific tumor within a particular time
and space of sample isolation [8,18–20]. After oncogenic alterations, GBM cells can be
differentiated and de-differentiated and can acquire stem cell properties [21,22]. All of
this suggests that genetic, epigenetic and metabolic alterations (reviewed in Section 3)
can be targeted, rather than simply killing a particular population of tumor cells, so are
valuable strategies to treat the disease. In addition, to tumor cells, the therapeutic targeting
of immune cells has gained high relevance in the last decade with the outstanding results
achieved by anti-tumoral immunotherapy in other types of cancer (i.e., melanoma and
lung cancer) [23].
The glioma tissue is infiltrated by many cells of different ontogenies, mostly resi-
dent microglia and tumor-infiltrating monocytes, which are denoted glioma-associated
macrophages/microglia (GAMs) and which can represent from 30 to 50% of the total cells
in the tumor [24–26]. Historically, macrophages and microglia had been thought to be
transposable in the TME as they share immunologic functions such as phagocytosis or
antigen presentation. However, in recent years, single-cell RNA sequencing (RNA-seq) per-
formed on GAMs from human glioma tissues have identified two phenotypically distinct
subsets associated with gene signatures of microglia-enriched and bone marrow-derived
macrophages [27]. These findings have also revealed key differences in the way the glioma
microenvironment shapes the transcriptional expression of these cells, in particular at the
level of genes involved in the secretion of inflammatory cytokine and antigen presenta-
tion [28–30]. Moreover, fate mapping analysis has revealed that microglia cells derive
from primitive myeloid progenitors which enter the brain during embryogenesis [31].
Conversely, circulating blood-monocytes typically enter the brain in pathological situations
and they differentiate into macrophages [32]. The exact contribution of microglia and circu-
lating blood-monocytes to the total pool of GAMs is still an open question. In some models,
microglia predominance has been reported [33], whereas others have demonstrated that
infiltrating monocytes are accountable for the majority of the GAM population [29,34].
Nevertheless, the key drivers of GAM recruitment are contextual, as these chemokines are
heterogeneously expressed among glioma, probably reflecting the diversity in glioma ge-
netics. Transcriptional classifications have revealed that this diversity influences the extent
of GAM infiltration. For instance, phosphatase and tensin homolog (PTEN) deficiency in
glioma drives macrophage infiltration via up-regulation of lysyl oxidase (LOX) [35] and in
mesenchymal GBMs neurofibromin 1 (NF1) deficiency results in increased GAM infiltration
compared with proneural or classical subtypes [18,36,37]. Notably, it is now recognized
that microglia and macrophages colonize different regions of gliomas. Monocyte-derived
macrophages are enriched in the tumor core where they occupy perivascular regions, while
microglia-derived tumor associated macrophages are typically found at the tumor periph-
ery [29,38]. Intravital 2-photon microscopy has revealed that these two subsets are also
morphologically distinct, monocyte-derived cells, being small and highly migratory, while
microglia are large, branched cells with highly active processes continuously extending
and retracting within tumors [39]. Future studies will be necessary to investigate whether
this divergence is related to a different activity and if these two populations affect tumor
growth differently.
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Although the mechanisms by which GAMs migrate to the tumor site are not entirely
clear, some studies have shown that their recruitment is mediated by various glioma-
derived factors such as CCL2, CX3CL1, SDF-1, CSF-1, GM-CSF and EGF, which act as
chemoattractants for GAMs and mediate the crosstalk between tumor cells and the in-
nate immune system [40] (Figure 1). In an NF1 mutant optic glioma murine model, Guo
et al. showed that CX3CL1 is a key chemokine responsible for the attraction of microglia
to the tumor [36]. Using CX3CR1- and CCR2-engineered murine models, Chen et al.
demonstrated that in glioma, microglia only express CX3CR1, whereas most inflamma-
tory monocytes/macrophages express both CX3CR1 and CCR2. This suggests that CCL2
is a major attractant for monocytes. Accordingly, in this model, CCL2 depletion led to
pro-longed survival [29]. CCL2 produced by both glioma cells and GAMs, has also been
shown to be essential for the recruitment of Treg cells and myeloid-derived suppressor
cells [41], which act as drivers of the immune-suppressive phenotype typical of these
tumors. Another recent study has suggested that osteopontin might also act as an im-
portant chemokine for macrophage recruitment to GBM tumors triggering its binding to
integrin αvβ5 [42]. T-cell dysfunction is also a hallmark of high-grade glioma, reflecting
the active immunosuppressive microenvironment which contributes to tumor immune
escape in patients. Takenaka et al. showed that expression of CCR2 is promoted in GAMs,
by the activation of the aryl hydrocarbon receptor (AHR), causing cytotoxic T-cell dys-
function through the CD39/CD73/adenosine pathway [43]. Anti-tumoral functions of
tumor-infiltrating lymphocytes (TILs) are impaired by multiple immunosuppressive factors
produced by GAMs and glioma cells and these factors are also more likely to up-regulate
multiple immune checkpoint molecules such as PD-1, TIM-3 and LAG-3 [44].
Phenotypically, it is now well documented that GAMs do not fit with the classical
M1/M2 macrophage dichotomy [45]. Originally suggested to be simplified as macrophages,
the phenotypic dichotomy assigned to T-helper cells (Th1/Th2), the M1/M2 denominations
of macrophages, were later described by Mantovani et al. as the two extreme poles of a
continuum of phenotypes and functions which could be acquired by very plastic immune
cells [46]. In this outline, classically activated M1-like macrophages present a prototyp-
ical pro-inflammatory response and anti-tumor functions, while alternatively, activated
M2-like macrophages, resembling tumor associated macrophages (TAMs), present anti-
inflammatory properties, at the same time as supporting tumor progression, angiogenesis
and metastasis and last of all, prevent adaptive immune responses [47].
In the context of glioma, using genome-wide microarray analysis, Szulzewsky et al.
revealed that a significant amount of genes up-regulated in GAMs do not fit with the
M1/M2 classification [48] and the single cell RNA-seq demonstrated that GAMs express
rather a mix of M1/M2 markers [27,49]. Despite such controversy, some typical M2 markers
of macrophage polarization which favor tumor progression have also been found in glioma,
some examples of which are provided below. Glioma heterogeneity may explain why
currently, the correlation between TAM infiltration in glioma and patient outcome is still
not clear. Some studies have reported on a positive correlation between patient outcomes
and the presence of TAMs in the vital tumor core in IDH1R132H-non-mutant GBMs [49]. In
another study, M2-like TAM numbers, identified with CD204, increased with malignancy
grade and were associated with a poor prognosis, while high IBA-1 intensity, a marker of
activated macrophages, correlated with a longer survival [50]. Similarly, compared with
IDH-wildtype GBM, a reduced number of macrophages which were more oriented towards
a pro-inflammatory M1-like activation state were found in IDH-mutant GBM patients,
possibly contributing to their prolonged survival [51]. As a whole, to understand GAM
biology in gliomas, it is critical to evaluate an integrated vision, including their ontogeny,
genomic and phenotypic diversity, differential location in the TME and functional activity.
Preclinical studies using animal models have shown that GAMs play a major role in
gliomagenesis and sustain tumor growth in both low-grade and high-grade gliomas. In
murine models, depletion of macrophages/microglia has led to a reduction in tumor
growth [32] and in line with this, some factors released by GAMs such as IL-6, IL-1β,
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EGF, STI-1 and TGF- β can promote tumor growth [32]. Indeed, the role of microglia in
glioma invasiveness has also been related to the secretion of SIP1, EGF and TGF-β [52].
Moreover, the activation of TLR2 expressed on microglia, has triggered the release of matrix
metalloproteinases (MMP2 and MMP9) [53,54], degrading the extracellular matrix and
facilitating the invasion of glioma cells. Toll-like receptor 4 (TLR4) signaling in microglia
has been shown to induce the release of IL-6 [55], a ligand of the signal transducer and
activator of the transcription 3 (STAT3) pathway in gliomas, which is also involved in
invasiveness [56]. Up-regulation of TGF-β and M-CSFR in the context of hypoxia, the
main feature of high-grade gliomas, has been shown to induce the M2-like protumoral
polarization of GAMs in murine glioma models [57,58]. The administration of acriflavine,
a hypoxia-inducible factor (HIF) inhibitor, hampered GAM enrichment and polarization
and significantly inhibited tumor progression [38].




Figure 1. Representation of interactions between glioma cells, macrophages/microglia and other components of the tu-
mor microenvironment. Macrophages and microglia (GAMs) are attracted to the tumor by several glioma cells-derived 
factors such as CCL2, CX3CL1, SDF-1, CSF-1, GM-CSF, EGF or OSTP, expressed in response to environmental stress 
(such as hypoxia) or GAMs-derived factors themselves. In the tumor microenvironment, GAMs exert a tumor-supporting 
activity through secretion of factors such as IL-6 (particularly in response to TLR4 activation in microglia), IL-1β, EGF, 
STI-1, TGF-β or VEGF that activate different signaling pathways (such as JNK, MAPK or STAT3 in glioma cells) pro-
moting proliferation, angiogenesis or invasion of tumor cells. In microglia, TLR2/6 activation has been shown to induce 
MMP2 and MMP9 expression, contributing to extracellular matrix degradation and tumor invasiveness. GAMs are also 
immunosuppressive effectors, especially via the expression of molecules which lead to T-cell dysfunction (CD80/86, 
PD-L1 or CD39). The phagocytic activity of GAMs is also impaired by the expression of CD47 (binding to SIRPα) by 
glioma cells. 
In the context of glioma, using genome-wide microarray analysis, Szulzewsky et al. 
revealed that a significant amount of genes up-regulated in GAMs do not fit with the 
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differential location in the TME and functional activity. Preclinical studies using animal 
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Figure 1. Repr sentation f interactions between glioma cells, macrophages/microglia and other components of the tumor
microenvironment. Macrophages and microglia (GAMs) are attracted to the tumor by several glioma cells-derived factors
such as CCL2, CX3CL1, SDF-1, CSF-1, GM-CSF, EGF or OSTP, expressed in response to environmental stress (such as
hypoxia) or GAMs-derived factors themselves. In the tumor microenvironment, GAMs exert a tumor-supporting activity
through secretion of factors such as IL-6 (particularly in response to TLR4 activation in microglia), IL-1β, EGF, STI-1, TGF-β
or VEGF that activ te different signaling pathways (such as JNK, MAPK or S AT3 in glioma cells) promoting pr liferation,
angiogenesis or invasion of tumor cells. I microglia, TLR2/6 activation has been shown to induc MMP2 and MMP9
expression, contributing to extracellular matrix degradation and tumor invasiveness. GAMs are also immunosuppressive
effectors, especially via the expression of molecules which lead to T-cell dysfunction (CD80/86, PD-L1 or CD39). The
phagocytic activity of GAMs is also impaired by the expression of CD47 (binding to SIRPα) by glioma cells.
To date, the vast majority of studies have demonstrated that macrophages/microglia
support GBM progression, although, in some cases, the ability of these cells to fight against
the tumor has been reported. This work has also revealed some molecular targets offering
possibilities for therapeutic intervention. Although, to our knowledge, studies testing
macrophage-directed therapies to treat GBM have still not been performed in zebrafish,
several investigations have already evaluated the role of macrophages and microglia in
zebrafish regeneration, tumor origin and progression [59,60] and in the context of other
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diseases [61,62]. Relevant zebrafish models for the study of GBM and the evaluation of
new treatments are reviewed in Sections 4 and 5, respectively.
3. Molecular Pathology in Glioblastoma
3.1. Genetic Mutations in Glioblastoma
Three important genetic events drive the development of GBM: the dysregulation of
growth factor signaling (EGF, PDGF, VEGF, etc.), the activation of the phosphatidylinositol-
3-OH-kinase (PI(3)K) pathway and the inactivation of the p53 and retinoblastoma (Rb)
tumor suppressor pathways [15]. IDH mutation occurs early in this process and stands
out as the main biomarker used in the 2016 CNS WHO [3] to identify and classify GBM
into the following types: (1) Glioblastoma IDH-wildtype (about 90% of cases): primary
or de novo GBM that predominates in patients of over 55 years of age. (2) Glioblastoma
IDH-mutant (about 10% of cases): secondary GBM that arises in younger patients. (3)
Glioblastoma not otherwise specified (NOS), when there is no information on this gene. The
mutation of arginine to histidine on codon 132 (p.R132H) is most frequent. In GBM, IDH1/2
mutations correlate with better prognosis, while no IDH3 mutations have been associated
yet. IDH mutation is strongly associated with 1p/19q codeletion and MGMT promoter
methylation, another common diagnostic biomarker, but are mutually exclusive with EGFR
amplification (gain of chromosome 7) and PTEN deletion (loss of chromosome 10) [63].
While the methylation of the MGMT gene promoter helps to estimate the sensitivity of
the tumor to alkylating agents such as TMZ, the relationship of IDH1/2 mutations with
response to chemotherapy remains controversial [64].
As an example of the dysregulation of growth signaling commonly occurring in GBM,
57% of GBM shows evidence of gains in function mutation and/or focal amplification of
EGFR, associated with an increase in the aggressiveness of these gliomas [14]. The most
frequent EGFR mutation in GBM that occurs, EGFRvIII, contains an in-frame deletion within
the extracellular domain that provides constitutive activation in a ligand-independent
fashion and promotes cell proliferation via the Ras-MAPK and PI3K pathways. Deletion of
PTEN displays a similar effect [65].
Cycle checkpoint proteins are often altered in cancer. p53 is a classic tumor suppressor
that regulates many genes involved in the cell cycle and apoptosis cascades. Inactivation
of p53 in GBM happens with a variety of mechanisms, including amplification of p53
inhibitors such as murine double minute (MDM) 2 and MDM4 (the latter appears most
commonly in tumors with no TP53 or telomerase reverse transcriptase (TERT) mutations),
deletion of p53 stabilizers such as p14/ARF and mutation in the TP53 gene which occurs
in 85% of GBMs [14]. Cyclin-dependent kinase inhibitor 2A and B (CDKN2A/B) copy
number losses (homozygous deletion of CDKN2A-p16INK4α in chromosome 9p) are linked
to the activation of the Rb pathway and to the proliferative niches that are observed in
gliomas [66]. Other alterations are responsible for the progression and difficult treatment of
GBM. Mutations in the promoter of the telomerase reverse transcriptase (TERTp) or ATRX
chromatin remodeler (ATRX) (mutually exclusive since they have similar functions), lead
to an increased lengthening of telomeres, allowing cells to overcome cellular senescence
and promoting immortalization [67,68].
3.2. Epigenetic Alterations in Glioblastoma
Genetic mutations are not the sole participants in the development and progression of
GBM. Epigenetics, as shown in many other types of cancer, plays an important role too.
GBM commonly presents an extended genomic epigenetic hypomethylation that allows
the transcription of multiple genes and is associated with rapid progression. Some of the
regions affected include D4Z4 (a polymorphic repeat structure), oncogenic genomic loci
such as SAT2 and the oncogene MAGE-A1 [69]. Mutations in the IDH1/2 genes induce
the production of an alternative metabolite, 2-hydroxyglutarate (2-HG) at the expense
of alpha ketoglutarate (α-KG) [70]. Since numerous enzymes involved in epigenetics
are dependent on α-KG (such as histone demethylases or ten-eleven translocation (TET)
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enzymes), the absence of this compound inhibits them, increasing the methylation of CpG
islands and histones. This intense methylome remodeling induces what is known as the
glioma CpG island methylator (G-CIMP) phenotype [71] and contrasts with the general
state of hypomethylation observed in GBM. The rare occurrence of IDH-mutation, a genetic
marker of secondary GBM that is mostly absent in primary GBM and its correlation with
better prognosis could indicate that this mutation is a hindrance in the progression from
low grade glioma (LGG) to GBM since it changes the epigenetic state of multiple genes
involved in important cellular processes. A glioma with IDH-mutation could require
further alterations to develop a more aggressive phenotype than gliomas without it.
A key example that highlights the importance of epigenetics in GBM comes from
MGMT alterations, one of the gold standard markers used for the characterization of the
disease. The methylation of the MGMT promoter is a biomarker with great diagnostic
value that correlates with good prognosis. Furthermore, as with the DNA alkylation
repair enzyme, the inhibition of MGMT expression enhances the anti-tumoral efficacy of
TMZ [72].
The epigenetic inactivation of many tumor suppressor genes has also been observed
in GBM. PTEN, p53, RB, p14 and p16 appear hypermethylated, along with some other
genes involved in key processes such as intercellular contact (PCDH-γ A11), the MAPK
pathway (SOCS1) and apoptosis (caspase-8) [69]. Histone deacetylases (HDACs) have
been implicated in many GBM tumors owing to the fact that their dysregulation influences
tumor progression, invasion and resistance to therapy. This is of special relevance in GBM
stem cells (GSC), where dysregulated HDAC expression has been associated with altered
signaling mechanisms like the sonic hedgehog (SHH) pathway (essential for stemness, via-
bility and radio-resistance) and the maintenance of mitochondrial functions and metabolic
adaptions [73].
3.3. Metabolic Changes in Glioblastoma
Metabolic switching is a well-known hallmark of cancer, including GBM and under-
standing and reprogramming metabolic pathways in tumors may yield new treatment
options [74]. Many cancers prefer aerobic glycolysis as their metabolic program of choice
to fulfill their bioenergetic and anabolic requirements for rapid growth and enhance their
survival in response to microenvironmental stress [75]. Aberrant expression of oncogenes
and tumor suppressor genes in GBM has correlated with changes in the expression and
activity of glycolytic transporters. Aerobic glycolysis, described in the 1920s by Otto War-
burg and his colleagues, known as the Warburg Effect, is defined as an increase in the rate
of glucose uptake and preferential production of lactate in the presence of oxygen in cancer
cells in compensation for insufficient OXPHOS [76,77]. The advantage that the Warburg
Effect confers to cancer cells is not completely clear. However, since ATP levels do not seem
to represent a limiting factor for tumor cells, it is generally accepted that aerobic glycolysis
in cancer promotes the use of NADH as a by-product of lactate to generate biomass and
lactate to acidify the microenvironment, facilitating tumor invasion [78]. Aerobic glycolysis,
which favors the deadly progression of GBM [79] (Figure 2), is controlled by glucose trans-
porters, GLUT1-4 and key glycolytic enzymes such as these: HK1-3, PFK1, GAPDH, PKM2
and LDHA; they are also influenced by several other cellular pathways and regulatory
proteins, including the following: PI3K/AKT, LKB1/AMPK, HIF-1/2, p53, EGFR, PDGFR
and c-MYC, among others. Data obtained from The Cancer Genome Atlas (TCGA) have
identified three core pathways which are frequently altered in more than 75% of GBMs: (i)
receptor tyrosine kinase/RAS/phosphatidylinositol 3 kinase (RTK/RAS/PI3K) signaling
(ii) p53 (iii) Rb signaling networks [15]. The analysis of 96 GBM human samples showed
aberrant overactivation in a number of RTKs and gain of function mutations such as in
EGFR (observed in 45% of GBM cases) which triggers RAS and AKT/PI3K cascades. As a
consequence, these downstream proliferative and metabolic signaling cascades have been
found to be up-regulated in GBM [15]. The activation of the mTOR signaling cascade by
AKT in GBM has led to the up-regulation of transcription factors such c-Myc [37], which
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up-regulates the expression of glycolytic genes [80]. AKT can also up-regulate glycol-
ysis by activating transcription and translocation of glucose transporters (GLUTs), also
up-regulated in GBM and other key enzymes such as Hexokinase II, involved in the first
step of glycolysis [81]. Therefore, alterations in oncogenes and tumor suppressor genes
controlling metabolism and metabolic enzymes underlying tumor progression in GBM are
targets of interest for the treatment of the disease.




Figure 2. Representation molecular mechanisms underlying the tumoral properties of glioma cells. A. Canonical pathway 
for miRNA biogenesis. miRNA are transcribed by RNA Pol II to produce the pri-miRNA that is later processed by the 
endonuclease Drosha/DGCR8 complex resulting in the formation of the hairpin precursor (pre-miRNA) that goes under a 
second cleavage by the endonuclease Dicer and generates a miRNA duplex. One of the strains, the mature ~22 nt (guide 
strain) is later loaded into the RISC (RNA Induced Silencing Complex) in association with Ago proteins. Via imperfect 
base-pairing to the 3′ UTR of its target mRNAs, miRNAs regulate the expression of its target genes by repressing mRNA 
translation and/or promoting mRNA degradation. B. miRNAs and target genes involved in GBM. Examples of miRNAs 
found to be downregulated or upregulated (indicated with the arrow) in GBM and their target genes involved in GBM 
pathology. C. Metabolic pathways altered in GBM. Metabolic switching towards aerobic glycolisis is a hallmark of cancer 
which controls the properties and functions of tumor cells, such as their increased proliferation or resistance to treat-
ments. The therapeutic intervention of metabolic pathways, described in this figure, may offer new opportunities for the 
treatment of GBM. 
The role of different miRNAs in regulating classic pathways and genes critical for 
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The therapeutic intervention of metabolic pathways, described in this figure, may offer new opportunities for the treatment
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It is of note, that mitochondria are a key cellular organelle regulating energy metabolism,
generation of free radicals and apoptosis. Additional metabolic signs of malignancy in
GBM have been linked to mitochondrial dysfunction and morphological abnormalities,
which have been correlated with compromised energy/ATP production via OXPHOS
and reduced apoptosis. Impaired mitochondrial metabolic capacity in glioma cells has
been evident from the identification of mutations in gene coding for IDH, described in
Section 3.1 and a principal component of the Krebs cycle. Mutations in the NADPH-
linked mitochondrial isoforms of IDH1 and IDH2 have led to impaired energy production
in the mitochondria and thus, provide clear evidence for mitochondrial dysfunction in
gliomas [82]. Indeed, IDH1 mutation not only causes 2-HB build-up, but also broad changes
in cellular metabolism. Due to changes in the expression of several key enzymes, GBMs
containing IDH1 mutations have been shown to exhibit a reduced glycolytic phenotype
compared to GBM without the mutation. Therefore, IDH status can also indicate distinct
glycolytic phenotypes of GBM, which may contribute to different clinical behavior of
tumors with and without the IDH1 mutations [80]. Cardiolipin, an important phospholipid
concentrated at the contact sites of outer and inner mitochondrial membranes and at the
electron transport chain (ETC) associates with respirasome complexes that are crucial
for mitochondrial function. Evidence from experimental and clinical studies has shown
defects in mitochondrial ETC associated with cardiolipin biosynthesis in gliomas. Thus,
the degree of faulty cardiolipin synthesis and its function indirectly affects the mitochon-
drial metabolic capacity and intrinsic apoptosis execution which have been found to be
impaired/malfunctioned in certain grades of glioma cells [82].
In addition, to genetic and epigenetic intervention, a broad variety of biological
molecules have been evaluated for the therapeutic manipulation of metabolic pathways,
including sugars, lipids and proteins [83]. Furthermore, with the same purpose, novel
post-transcriptional regulators, such as miRNAs (reviewed below), are of utmost interest.
3.4. miRNAs in Glioblastoma
miRNAs are small (18–25 nucleotides), evolutionarily conserved, non-coding RNAs
with important functions in gene regulation, acting predominantly at the posttranscrip-
tional level. miRNAs are transcribed in the nucleus by RNA polymerase II into primary
transcripts (pri-miRNAs) that are then processed sequentially in the nucleus and cytoplasm
by a complex of RNase III-endonucleases, namely Drosha and Dicer [73,84,85], (Figure 2).
Drosha, specifically, processes the pri-miRNA transcript to a 70–100 nucleotide stem-loop
precursor (pre-miRNA), which is then delivered to the cytoplasm by Exportin 5, where it is
subsequently cleaved by Dicer to produce a miRNA duplex [73,84]. The resulting duplex is
then incorporated into the RNA-induced silencing complex (RISC) in association with an
Ago family member. One of the strands (the passenger strand) is degraded, while the other
strand (the mature miRNA) remains associated with the Ago protein and binds to partially
complementary sites in mRNAs. By way of binding to the 3′UTR of target messenger
RNAs (mRNAs), miRNAs repress translation or induce mRNA degradation [86,87].
Over the past two decades, miRNAs have been shown to regulate many physiological
processes in the cells and they have been implicated in a wide range of pathological condi-
tions, including cancer. Around 50% of the human-miRNA-encoded genes are located in
genetic loci associated with cancer [88] and nearly all tumors show dysregulated miRNA
expression signatures [89]. These alterations frequently correlate with up-regulation of
oncogenes and/or downregulation of tumor suppressor-genes, therefore, promoting the
development of the tumor. The pattern of miRNA expression is now being used, together
with gene-expression profiling to stratify GBM patients into different groups [90]. In addi-
tion, miRNAs have multiple targets, allowing them to modulate many pathological aspects
critical to cancer progression, including proliferation, cell death, metastasis, angiogene-
sis and drug resistance. A number of miRNAs have been identified that interact with
known genes and pathways that underlie GBM [91] and some of them have been placed as
biomarkers [92] and predictors of survival and outcomes [93].
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The role of different miRNAs in regulating classic pathways and genes critical for
the GBM genesis at the post-transcriptional level has been described. These include p53,
EGFR, PDGFR, PTEN, PI3K and AKT and MGMT, among others [94] (Figure 2). MicroRNA
signatures with deficient patterns of expression have been found for several miRNAs
such as the miR-7, miR-34a, miR-128, miR-124, miR-137 and miR-181 families and it
has been observed that their overexpression negatively impacts GBM development [95].
On the contrary, multiple up-regulated miRNAs have been described, miR-21 being the
first-investigated oncomiR which plays crucial roles in deleterious processes in GBM by
targeting aforementioned genes, as well as others involved in proliferation, cell survival
and drug resistance [95]. Other examples of miRNA up-regulated in GBM with important
functions in gliomagenesis include the miR-17-92 cluster, miR-10b, miR-15b, miR-26a,
miR-93, miR-148, miR-182 and miR-221/222 [95]. In addition, to specific tissue-signatures
associated with GBM tumors, miRNAs have been found in extracellular vesicles from
GBM in circulation. This finding has encouraged studies to explore their use as potential
biomarkers with diagnostic value by non-invasive techniques, such as liquid biopsies
from GBM patients [94,96]. Along with the modulation of oncogenic signaling pathways
and tumor suppressors, miRNAs have also been shown to govern the expression of key
metabolic genes in the context of many diseases, as well as in GBM [80,97–99] (Figure 2).
Thus, by targeting key proteins or enzymes that participate in processes like glycolysis,
oxidative phosphorylation, glutamine, glucose and lipid metabolism, several microRNAs
can contribute to the characteristic metabolic switching in cancer and GBM [85]. Some
examples affecting glycolysis include miR-106a and miR-143 which targets the GLUT-3
transporter, as well as miR-326 targeting HK-2 and let-7a, which represses PKM2 expression.
Other miRNAs interfere with mitochondrial function and energy metabolism (i.e., let-7,
miR-16 and miR-23) or regulate mitochondrial proteins (i.e., ATP5A1 and ATP5B) in GBM.
As aerobic glycolysis is a hallmark of GBM tumors, the ability of certain miRNAs to
regulate glycolytic metabolism in GBM via regulating oncogenes and tumor suppressor
genes in the RTK pathways and their downstream effector pathways such as the PI3K/AKT
pathway, is of interest for therapeutic purposes [100]. Undoubtedly, further research efforts
will elucidate novel roles of miRNAs and other posttranscriptional regulators in energy
metabolism, providing new potential targets for the treatment of GBM and other diseases.
To our knowledge, no studies with therapeutic purposes have yet been performed which
manipulate miRNAs in GBM zebrafish models.
Overall, this knowledge and further understanding of molecular mechanisms con-
trolling GBM pathology will offer numerous possibilities for therapeutic manipulation of
signaling pathways, often intertwined, which can theoretically be treated with different
drugs at the genetic, epigenetic or metabolic level. Genetic or xenotransplantation models
of zebrafish selectively manipulated in these key pathways are particularly suited to the
testing of new therapeutic strategies. In this context, miRNAs represent an attractive target
which can be efficiently blocked by (i) sequence-specific oligonucleotides, (ii) antisense
approaches or (iii) miRNA sponges.
4. Zebrafish Models of Glioblastoma
4.1. Advantages and Limitations of Current Zebrafish Models for Modelling Human Disease
Over the last few decades, advances in biotechnology have allowed improved in vitro
and in vivo models of human disease to be developed, underlying pathogenic mechanisms
to be understood and therapeutic approaches to be improved. Although in vitro systems
for cancer research have experienced significant advances, living organisms bearing tumors
are still necessary to recreate the “atmosphere” of human tumors; such examples could
be the interaction between tumor cells and immune cells in the primary tumor or at
metastatic sites, endocrine or metabolic factors altering tumor development, not to mention
biodistribution, pharmacokinetics or efficacy of new drugs [101,102]. Despite rodents,
mainly mice, being the most commonly used animal model for in vivo studies, zebrafish
models are increasingly being used for cancer and drug discovery research. Since the early
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1960s, when it was introduced as an animal model to study vertebrate developmental
biology and genetics, zebrafish has progressively been adopted as a useful model for
unraveling the cellular, molecular and genetic features of several human diseases, including
cancer [12].
The success of zebrafish in biomedical research can be explained by its inherent
biological features and economic issues. Zebrafish are able to produce between 200 and 400
embryos per couple once a week and their small size allows handling large numbers of fish
in reduced space. Thus, zebrafish models enable high-throughput assays with significant
statistical power, cost-efficient experiments and fewer ethical issues than murine models.
The optical transparency of embryos allows direct visualization of development and makes
the imaging and tracking of injected tumor cells possible without the need of invasive
techniques [103]. Its translucent nature also enables the establishment of different cell or
tissue-specific reporter lines.
Zebrafish, or murine, xenograft tumor models are commonly used in cancer research
and are very useful for testing new drugs. However, these models present limitations
related to the lack of a fully functional immune system as required to favor the implantation
and growth of tumor cells in other species. Zebrafish complete their basic development
in the first 24 h post-fertilization (hpf) but they lack an adaptive immune system until the
first 12 to 14 days of development, thus allowing this window for the implantation and
progression of the cancer cells, without the need to use immunocompromised fish [104].
Despite the peculiarity of the species initially being considered a limitation, recent studies
have used these features as an opportunity for rigorous experiments, with some strategies
being implemented for research on immune cells. Appropriate zebrafish models are
routinely used for studies of innate immunity, using fluorescently labeled macrophages or
neutrophils (i.e., GFP or RFP) as these cells are already available from the first stages of
zebrafish development. As a solution for studying adaptive immunity, the development
of human T cell tumor-implanted zebrafish models and the subsequent eradication of
cancer cells have proven to be useful for precision medicine platforms when assessing the
anticancer effects of cellular immunotherapy in vivo [105].
Nevertheless, xenografts are not applicable for every tumor type. Due to the phy-
logenetic distance between teleost fish and mammals, not all human organs are present
in zebrafish. In order to overcome this hurdle, it has been suggested that analogous
structures, such as gills could be used as a substitute for lungs [106]. With respect to
brain tumor modeling, despite the differences between zebrafish and humans, it is worth
noting that the most relevant brain regions and subdivisions, as well as cell types, dif-
ferentiation, connectivity, signaling pathways and gene expression patterns, are highly
conserved [13,107]. The immaturity of certain tissues in zebrafish embryos (i.e., myelinated
axonal sheaths) does have to be considered though, as this may affect the development of
certain tumors [108,109].
Concerning genetics, the release of the sequence assembly of the zebrafish genome has
revealed that around 70% of human genes are shared in zebrafish with more than 80% of
them being human disease-related genes [110]. Moreover, the relative cost-effectiveness and
ease to perform genetic manipulations in zebrafish embryos [111] increases its attractiveness
as a form of generating genetic cancer models. On the other hand, some critical oncogenic
factors such as INK4α/ARF are not expressed in zebrafish which rules out studies related
to these pathways [112]. Similar issues might be encountered for epigenetic or metabolic
alterations related to cancer in zebrafish, but the amount of information in this regard is
still very limited and has been reviewed by others [102,113].
Taking these pros and cons into consideration, below we describe relevant genetic and
transplantation strategies that have been investigated using zebrafish as a model for GBM.
4.2. Genetic Zebrafish Models of Glioblastoma
Genetic approaches for disease modeling in zebrafish comprise several strategies
ranging from gene-targeted mutations to transient or stable over-/downregulation of genes
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of interest. Numerous cancer models have been established by transgenic expression of
human and murine oncogenes in zebrafish (i.e., KRASG12V, HRASG12V and BRAFV600E)
providing information about the role of selected genes in tumorigenesis [114–116]. Further-
more, zebrafish cell- and tissue-specific reporter lines have been developed to study cancer-
related properties such as tumor cell growth, migration, invasion, angiogenesis, drug re-
sponses and interactions with neural and immune cells. For instance, Tg(mpx:GFP) for neu-
trophils [117] and Tg(mpeg1:EGFP) or Tg(mpeg1:mCherry) for macrophages [118,119] are
frequently used. Among different methodologies for genetic manipulation, the Gal4/UAS
system has been widely used for the activation of gene expression [120]. Other genetic
models which could be useful for research in cancer or other diseases have recently been
reviewed by Pensado-López et al. [107].
To model GBM-like tumors in zebrafish, several genetic approaches have been used
(Table 1). To illustrate this, Ju et al. used a binary transgenic approach co-expressing
zebrafish Smoa1 involved in the Shh pathway, with human AKT1 so as to model GBM-
like tumors in the brain, retina and spinal cord [121]. The same group also developed
the first animal model of gliomagenesis by Shh activation in neural progenitor cells by
way of the transgenic expression of Smoa1 under the krt5 neural promoter [122]. In
zebrafish, KRASG12V overexpression under the neural promoters krt5 and gfap (specific
for neurons, glial cells and astrocytes) led to malignant tumors in the cranial cavity and
parenchymal brain tumors respectively, highlighting that different tumor initiating cells
may well determine the tumor type and demonstrating that tumorigenesis is driven by
the activation of the canonical Ras and mTOR pathways [123]. Along the same lines,
Mayrhofer et al. observed brain tumor development with the expression of HRASG12V,
YAPS5A, KRASG12V, AKT, EGFRvIII and BRAFV600E oncogenes under the control of the zic4
enhancer, proliferating domain of developing nervous system. The somatic expression
of activated RAS promoted brain tumors and/or heterotopia, suggesting their possible
origin from a benign developmental lesion. Analyses of global RNA expression revealed
that developed tumors resembled mesenchymal GBMs with a strong YAP component,
suggesting YAP as a hallmark of malignant brain tumor and providing a useful model for
preclinical drug screening for this GBM subtype [124]. As somatic missense mutations in
the IDH1 gene are frequently found in gliomas and have been related with better patient
survival, several transgenic zebrafish lines expressing various IDH1 mutations have been
established to clarify their role in tumor development [125].
Transient genetic modifications in zebrafish are commonly performed by the morpholino-
based (MO) expression silencing, which enables the binding of the oligonucleotide to a
desired target, knocking down the gene without sequence modification [126]. MOs have
been extensively used to unravel the basis of GBM-cells, to elucidate molecular mechanisms
and to find novel prognosis markers and therapeutic strategies. As an example of this, ex-
periments knocking down Ephrin-B3 ortholog and co-silencing EphA4 in zebrafish allowed
impairments to be found in the formation of intersegmental vessels (ISVs) associated with
EphA4-related apoptosis and angiogenesis, thus suggesting EphA4-induced cell death
as an opportunity to slow GBM growth [127]. Similarly, the involvement of Plexin-A1 in
the development of blood vessels and angiogenic sprouts in ISVs was demonstrated by
Plexin-A1 knock down in zebrafish models [128].
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Table 1. Genetic approaches using zebrafish for modeling GBM.
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Table 1. Cont.
Genetic Approach System Gene/Protein Zebrafish Strain Notable Results Reference
Knockout
ENU/ZFNs nf1a/nf1b Tg(gfap:GFP)/Tg(sox10:GFP)/Tg(olig2:GFP)/p53-/-
High grade gliomas and MPNSTs.














are initiated by Ca2+-dependent
ATP release from pre-neoplastic
cells and their coupling with
P2ry12
[134]
Overexpression Human GLUD2 mRNAinjection GLUD2 WT
Impaired glial cell proliferation.
Novel target for GBM progression [135]
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Dysregulation of cellular energetics and alteration of tumor cell metabolism, in partic-
ular glutamine metabolism, has been investigated using zebrafish models. For instance,
glutamate dehydrogenase 2 (GLUD2) mRNA injection in zebrafish resulted in glial cell
proliferation impairment while neuronal development was not affected, suggesting a novel
potential drug target for GBM progression [135]. Additional studies combining the use of
MOs and xenotransplantation in zebrafish for GBM research are reviewed in Section 4.3.
Other mutagenesis approaches used to generate stable zebrafish cancer models in-
clude: Targeting Induced Local Lesions in Genomes (TILLING), based on the exposure to
the mutagen ethyl-nitrosourea (ENU), Zinc Finger Nucleases (ZFNs) and Transcription
Activator-Like Effector Nucleases (TALENs), both based on nucleases and, most recently,
CRISPR/Cas9 technology. These approaches have been used to demonstrate that NF1 loss
increases penetrance of high-grade gliomas and malignant peripheral nerve sheath tumors
in zebrafish with downregulation in telomerase and hyperactivation of ERK and mTOR
pathways [133], as has also been observed in mice and human NF1-derived malignant
peripheral nerve sheath tumors (MPNSTs) and gliomas [132].
A larval zebrafish model mimicking the earliest stages of brain tumor growth has been
developed by overexpressing a cancer-promoting version of the human AKT1 oncogene in
neural cells, under the neural-specific beta tubulin promoter, using the LexPR transcrip-
tional activator system combined with macrophage and microglia reporters. In response to
the activation of this oncogene, an increase in macrophage and microglia cell numbers was
found in the brain, mediated by the SDF1b-CXCR4b signaling pathway which interacts
with neoplastic cells by way of Ca2+-dependent ATP release and its coupling with the
microglia P2ry12 receptor, inducing their proliferation. This infiltration did not result in
enhanced phagocytic activity of the microglia towards the preneoplastic cells even though
that is the primary role of the cells in the central nervous system [130,134]. Furthermore,
macrophage depletion resulted in reduced proliferation of the tumor cells [130]. Along the
same lines, in 2016, a zebrafish model of glioma with labeled macrophages/microglia
demonstrated that microglia do not engulf or phagocytose glioma cells, but rather promote
their growth [136]. It is worth pointing out that this effect has been attributed to overexpres-
sion of CD47 on glioma cells, which binds to SIRPα on the phagocytic cells to inhibit their
phagocytic activity [10]. Accordingly, in patients, CD47 expression increases with the grade
and is associated with lower survival rates [137]. These findings suggest the use of anti-
CD47 therapy for the treatment of glioma to improve the ability of macrophages/microglia
to fight against the tumor.
As a whole, genetic zebrafish models have been successfully used to study brain
tumors from their initial stages of development, offering the possibility to manipulate
selected pathways relevant in glioma and immune-related cells (i.e., macrophages), to
study their influence on the progression of the disease and also to look into the efficacy of
their therapeutic intervention.
4.3. Zebrafish Xenotransplantation Glioblastoma Models
Zebrafish xenografts commonly consist of the implantation of labeled cell lines of
human or murine origin, or patient-derived cells into appropriate anatomical sites to
generate in vivo heterotopic or orthotopic tumor models, which allow the tracking of a
cancer cell’s survival, proliferation, metastasis, angiogenic potential, interaction with the
microenvironment and response or resistance to new treatments [138–140]. The vast major-
ity of zebrafish xenografts have been injected at 2 days post-fertilization (dpf), preventing
tumor rejection, as the zebrafish adaptive immune system is not mature until 4–6 weeks
post-fertilization, and during the first 12–14 days of development, only innate immune
cells are present. [104,141]. Additionally, the transparency of the embryo at these early
stages of development allows tumor cells to be tracked at a high resolution and the avail-
ability of reporter lines enables cell-host interactions to be inferred [140]. Although the
injection site may depend on the cell type and the biological events to be interrogated, most
implantations are performed in the yolk sac, the duct of Cuvier, the perivitelline space or
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the intraperitoneal cavity in the case of adult xenografts [113,139,142–149] (Figure 3). In the
particular context of brain tumors, the likelihood of developing orthotopic tumors prompts
most researchers to inject cells directly into the ventricles or the hindbrain-midbrain bound-
ary. Although this is not optimal, it allows to study the growth of cancer cells in an
environment which resembles the nervous system.
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hpf); (b) Duct of Cuvier, perivitelline space and yolk sac in zebrafish embryo (48 hpf); (c) Embryo
brain (48 hpf); (d) Intraperitoneal cavity in adult zebrafish. Images (a–c) were acquired in our lab
with a stereomicroscope (AZ-100 Multizoom, Nikon). Image (d) was acquired in our lab with a
Samsung Galaxy A70.
Xenograft models have provided information about GBM initiation and progression
(Table 2) and have allowed investigations of novel therapeutic approaches (reviewed in
Section 5). To investigate brain cancer biology, human far-red-labeled GBM cells were
injected in zebrafish larvae to follow tumor progression, size, shape and brightness [150]. In
this study, large numbers of tumor cells and cellular divisions over time were quantified by
a combination of stereomicroscopy, light sheet fluorescence microscopy and flow cytometry.
A robust, fast and automatable transplantation approach has recently been reported by
Pudelko et al. to establish orthotopic GBM tumors in zebrafish. By injecting GBM cell lines
or patient-derived samples into zebrafish blastulas, they observed their robust migration
into the developing nervous system, already establishing an orthotopic intracranial tumor
at 24 h post-injection (hpi). This approach avoids the technically challenging intracra-
nial transplantation of single embryos, thus enabling the transplantation of hundreds of
embryos per hour and providing an orthotopic vertebrate GBM model useful for drug
discovery screens [151]. Others have used stem cells cultures derived from pediatric high-
grade glioma tumors to generate orthotopic brain tumors, conserving stemness properties
and resembling human gliomas [152]. The engraftment of patient-derived GBM cells in
adult zebrafish has been assessed in an optically clear, imm nocompromised homozygous
compound mutant (prkdc−/−, il2rga−/−). Tumor cells robustly engrafte and proliferated
showing similar growth kinetics and histopathol gy to tho e bserved in a mouse mod l.
Nevertheless, in this case, the requirement to pre-treat animals with clodronate liposomes
in order to inhibi early m crophage ingestion might be to toxic, restricting t e us ful-
ness of t is mod l [153]. The injection of glioma cells intracranially or in the y lk sac of
2 dpf embryos was used to demonstrate that chondroitin 4-sulfate (C4S) and chondroitin
6-sulfate (C6S) promote GBM cell migration and invasion [154]. The impact of nitric xide
(NO) in tumor progression was confirmed in 2 dpf Tg(fli1:EGFP) embryos injected in the
Cancers 2021, 13, 1087 17 of 37
yolk sac with rat GBM-labeled cells (GV1A1) [155]. Cells were able to grow and produce
NO, as confirmed with diamino-fluoresceins and diamino-rhodamines, and the increase in
the NO synthases (nos1 and nos2a). Furthermore, neovascularization and increase in vegfa
and cyclin D1 expression were observed in 85% of the embryos with NO production, and
the addition of a NO scavenger (CPTIO) reduced vegfa and cyclin D1 expression as well as
the number of endothelial cells, suggesting that the reduction in NO levels by nitric oxide
scavenging could be an efficient approach for the treatment of glioma.
Table 2. Xenograft approaches using zebrafish for modeling GBM.
Injection
Site Cell Line Stage Zebrafish Strain Notable Results Reference
Yolk sac
Far-red CCF-STTG1 48 hpf WT
Tumor progression size, shape, brightness and
quantification of tumor cells, by combination of
LSFM and flow cytometry
[150]
GV1A1-CM-DiI 48 hpf Tg(fli1:EGFP) Impact of NO production via vegfa and cyclinD1 expression [155]
U87-RFP
(TGF-β1-treated) 48 hpf Tg(fli:GFP)
Increase in newly-formed blood vessels and
macrophage accumulation in the brain region [156]
U87-RPF
(CSCs-enriched cells) 48 hpf Tg(fli:GFP)
Up-regulation of CD133 and MMP9 leads to
glioma invasiveness [157]
U373-GFP
(GBM stem-like cells) 48 hpf Tg(kdr:mCherry)
RAC proteins promote aggressiveness and poor
prognosis of GBM [158]
Yolk sac/
Brain U251- CM-DiI 48 hpf WT
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52 hpf WT MSC-GBM cell crosstalk affects invasion in acell type-specific manner [160]
D54-MG/D2159MG 72 hpf Tg(fli1a:eGFP); casper
Cell attachment and migration through the




U87MG 48 hpf Tg(fli1:EGFP)
Increase in tumor growth and angiogenesis.




knockdown embryos 48 hpf Tg(fli:EGGP)
lama5 suppresses invasion but increases tumor
formation via VEGF [163]
Intraperitoneal Patient-derived Adult Casper, prkdc−/− , il2rga−/− Successful tumor engraftment at physiologicaltemperature (37 ◦C) [146]
The mechanisms of glioma-vessel interactions, angiogenesis and tumor invasion have
also been studied in zebrafish models. Umans et al. intracranially injected an adult glioma
cell line and a pediatric patient derived xenoline into Tg(fli1a:eGFP) casper embryos at
3 dpf and observed the attachment of cells to the brain vasculature within 24 hpi, as well
as their expansion and migration along the vascular network by 7 dpf [161]. The same cells
injected into the trunk failed to interact with the vasculature and moved rostrally towards
the brain, highlighting the importance of the microenvironment. Similarly, zebrafish
xenograft models were used to elucidate the role of mesenchymal stems cells (MSCs) in
GBM progression [160,164]. By co-injecting bone marrow-derived MSCs with two different
GBM cell lines (U373 or U87) in the brain of zebrafish embryos, intratumor heterogeneity
was observed as a consequence of the differential crosstalk between MSC-GBM cells,
affecting invasion in a cell type-specific manner [160]. Such different tumor progression
depending on the cell type and its interaction with microglia was demonstrated using a
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macrophage/microglia-labeled transgenic zebrafish line or the interferon regulatory factor
8 mutant (irf8−/−), which does not contain microglia [136]. The injection of U87 or U251
cells into the optic tectum resulted in tumor progression and the attraction of microglia
in both cell types although interactions and infiltration differed in number and nature.
The injection of cells in irf8−/− decreased proliferation and survival, demonstrating the
protumoral activity of microglia and how important it is to consider their differential
response to distinct cell types when developing immunotherapies to treat gliomas. TGF-
β was also shown to enhance tumor-induced angiogenesis via the JNK pathway and
macrophage infiltration in a zebrafish glioma xenograft model [156]. Pretreatment of
U87 GBM cells with TGF-β1 and subsequent injection into the yolk sac of Tg(fli:GFP)
embryos at 2dpf led to a significant increase in newly-formed blood vessels, as well as in
macrophage accumulation in the brain region, tail and yolk sac. Additionally, the treatment
of xenografted embryos with a JNK inhibitor resulted in a decrease in angiogenesis, which
may well be a powerful model for anti-angiogenesis drug screenings. The same group
established a tumor invasion model in 2dpf Tg(fli:EGFP) embryos by transplanting the U87
cell line and its derived cancer stem cells (CSCs) [157]. CSCs enriched from U87 cells spread
rapidly through the vessels, acquiring a protrusive appearance to establish metastasis and
their invasiveness correlated with the up-regulation of the stem cell marker CD133 and
the MMP9. Furthermore, CSC invasion was markedly inhibited by an MMP9 inhibitor,
validating the use of zebrafish models to study the mechanisms underlying the invasion
and metastatic behavior of glioma cells.
To examine the effects of Rac proteins on GBM progression in vivo, Lai et al. injected
GFP-labeled U373- tumor sphere cells (GBM stem-like cells) in the yolk sac of 2 dpf
Tg(kdr:mCherry) embryos with labeled endothelial cells, harboring control scramble short
haipin (shRNA), Rac shRNAs (shRacs) and Rac 1–3 cDNAs, to silence or overexpress Rac
proteins respectively [158]. They observed higher survival rates and lower incidence of
angiogenesis in embryos bearing the tumor spheres derived from U373-MG cells with
shRacs than controls, correlating the expression of Rac proteins with aggressiveness and
poor prognosis in GBM. RECQ1 helicase plays an important role in tumor progression,
as its expression is highly elevated in GBM [159]. shRNA-silencing of RECQ1 in U87
cells transplanted into 2 dpf zebrafish brains resulted in decreased tumor growth. MOs
were used to knock down lysine (K)-specific methyltransferase 2A (KMT2A), involved in
glioma progression [162], resulting in downregulated proliferation of neural progenitors,
premature differentiation of neurons and impaired gliogenesis [165]. KMT2A-knockdown
in U87MG cells transplanted into 2 dpf Tg(fli1:EGFP) zebrafish brains increased both tumor
growth and angiogenesis, even when embryos were treated with an immune suppressant
(dexamethasone), revealing that KMT2A acts negatively on tumor growth in contrast with
the previous conception of KMT2A as an oncogene in tumorigenesis [162]. Gamble et al.
discovered that adhesion to laminin subunit alpha 5 (lama5), an important component of
blood vessels, decreases GBM cell invasion and promotes the formation of blood vessel
dependent microtumors. With 4D individual cell tracking technology and U251MG cells,
xenotransplantation in the hindbrain ventricle of Tg(fli1:EGFP) 2 dpf embryos, proliferation,
dispersion, microtumor formation and cell/blood vessel association were confirmed [163].
Nevertheless, lama5 knockdown by MOs resulted in significantly higher cell dispersion
and mobility whereas microtumor formation was lower. Thus, lama5 increases GBM cell
attachment to blood vessels by elevating VEGF activity, which in turn suppresses invasion
but increases tumor formation.
Overall, a broad variety of xenograft zebrafish models of GBM have been established
with different purposes. Although orthotopic models are preferable to better mimic the
human pathology, heterotopic models allowing for the easier implantation of cells can be
used for a preliminary screening of drugs and/or to study particular mechanisms.
Cancers 2021, 13, 1087 19 of 37
5. Evaluation of New Treatments for GBM Using Zebrafish Models
GBM is a devastating disease, not only because of its particular aggressive nature, but
also due to the very limited efficacy of the therapeutic options currently available [166,167].
The standard of care is surgery, followed by radiotherapy and TMZ, a DNA alkylating
agent that can be administered orally [166,168]. Recurrence of GBM is very high and
survival after treatment is commonly 12–15 months due to the following issues [166,167]:
(i) difficulties to remove all tumors due to their great invasive and proliferative capac-
ity [167,168], (ii) their high mutational capacity, which rapidly generates resistance to
chemotherapies, such as TMZ [166,169]. In addition to therapies targeting cancer cells,
novel anti-tumoral immunotherapies have been evaluated and numerous clinical trials
using immune checkpoint inhibitors (ICIs, i.e., anti-PD1 and anti-CTLA4) are ongoing.
Furthermore, therapeutic strategies to reprogram the tumor microenvironment or to nor-
malize angiogenesis, including targeting and re-educating TAMs towards M1 anti-tumoral
macrophages are of particular interest. For example, intratumoral delivery of IL-12 using
a genetically-modified virus, alone or in combination with ICIs, showed good results in
preclinical murine models [84]. For the genetic, epigenetic and metabolic reprogramming of
GBM tumors, several approaches are being investigated. For instance, histone deacetylate
inhibitors and shRNAs towards HDAC1 and 2 [170] or SIRT1, alone, or in combination
with radiotherapy, showed antitumoral efficacy [171,172]. Either to kill cancer cells or to
reprogram the TME, miRNA manipulation represents a very attractive target (reviewed in
Section 3.4). Other major issues for the effective treatment of brain tumors are the ability of
the drugs to cross the blood–brain–barrier (BBB) and/or the absence of systemic toxicity.
In this scenario, zebrafish models have arisen as very useful pre-clinical models to evaluate
in vivo the anti-tumoral efficacy of new drugs and their ability to reach and interact with
target cells (i.e., cancer cells and macrophages), as well as to modulate the TME (i.e., an-
giogenesis) and their biodistribution ability to cross the blood–brain–barrier (BBB) and/or
toxicity. A brief description of relevant studies using mainly zebrafish xenograft models
for testing GBM therapies is provided below and in Table 3.
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Table 3. Treatments for GBM evaluated using xenograft zebrafish models.





36 hpf Brain ventricle
TMZ enhances survival and decreases
tumor growth. NRP-1 abrogation improves
the effect of TMZ
[173]
TNB Tg(flk:eGFP)- Casper U87-RFP or U251-RFP 72 hpf Brain TNB is able to cross the BBB and inhibitstumor progression [174]






Diverse differentiation patterns in cells, but
both positive for Sox2 and responsive
to therapeutics
[168]
TMZ Casper GBM9-GFPneurospheres 36 hpf MHB
Putative GBM stem cells are more resistant
and might contribute to tumor regrowth [169]
TMZ/Onalespib WT U251HF-GFP 36 hpf MHB Combination of Onalespib with TMZreduces tumor burden and extends survival [176]
HK WT U87MG-CM-DiI 48 hpf Yolk sac Inhibition of tumor growth and metastasis [177]
Dox-HK-MPEG-PCL
micelles Tg (flk: eGFP)/WT U87- GFP 14 and 48 hpf Perivitelline space Anti-angiogenic and anti-tumor properties [178]








36 hpf MHB Anti-tumor efficacy of CMP5,without toxicity [180]
HDAC class






42MGBA-TMZres-DiI 36 hpf Intracranial
Shift to ERRb2 isoform and suppression of
growth and migration in
TMZ-resistant cells
[182]
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Table 3. Cont.
Treatment Zebrafish Strain Cell Line Stage Injection Site Remarkable Results Reference
5-FU/Erlotinib Tg(fli1:eGFP) ConditionedGBMERBB2-RFP 30 dpf Cerebrum (intranasally)
Mouse brain tumors can grow








Intracranial Real-time death of glioma stem cells (GSCs)and tumor volume decrease [184]




neural stem cell) 24 hpf Brain Reduction in GBM formation [185]
Axitinib, Suntinib,
Vatalani/Nordy Tg (fli1:EGFP) GSCs U87- derived 48 hpf Yolk sac
Inhibition of tumor-induced vessel
formation. Model for anti-GSC
drug evaluation
[186]
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5.1. Treatments Tested in Zebrafish by Xenotransplantation of GBM Cell Lines
Zebrafish xenotransplants have allowed GBM growth and response to treatment to be
studied in real time, which, in turn, enables an evaluation of the proliferative, migratory,
invasive and angiogenic status of the tumor. In these studies, TMZ was commonly used
as the reference treatment and for positive control. For example, 2-methoxy-6-acetyl-
7methyljuglone (MAM), a natural product that induced necroptosis in colon and lung
cancer cells, injected into U251-xenograft zebrafish models showed similar anti-tumoral
efficacy to TMZ at very low doses [175]. A comparison between TMZ and bortezomib,
a proteasome inhibitor, in GBM9-xenograft zebrafish, showed similar tumor reduction
for both drugs but lower survival for bortezomib [168]. Using the same model, tumor
regrowth after TMZ treatment was demonstrated for cancer stem cells expressing Sox2
and GFAP, revealing molecular mechanisms underlying resistance to treatment [169].
In another study, the VEGF and its coreceptor and proangiogenic factor neuropilin-1
(NRP-1) were knocked down in two human patient–derived GBM cell lines, GBM1A and
GBM22, previously reported to be resistant to TMZ, before implantation into the brain
ventricle region of 36 hpf embryos [173]. Although deletion of both VEGF and NRP-1
were able to inhibit tumor growth, TMZ treatment showed better results in combination
with NRP-1 abrogation. Onalaspib, an inhibitor of heat shock protein 90 (HSP90), alone
or in combination with TMZ, was tested in GBM zebrafish models that were injected in
the mid-hindbrain with U251HF-GFP cells, showing better activity for the combination
therapy [176]. Honokiol, a natural compound with anti-inflammatory, anti-microbial, anti-
oxidative and anti-depressant properties, was tested for its anti-tumoral activity in zebrafish
models using U87MG cells injected into the yolk sac. Honokiol prevented the migration
of the cancer cells to the brain and tail, reduced migratory, invasive and proliferative
tumor activity with an increase in caspase-2 and inhibited the EGFR, CD133, Nestin, STAT3
phosphorylation and AKT/ERK signaling pathways [177]. In the U87MG-zebrafish model,
micellar-nanoparticles (NPs) loaded with honokiol and doxorubicin prevented tumor
progression; in an embryonic angiogenesis-zebrafish model Tg(flk1: EGFP), the same NPs
inhibited the growth of intersegmental vessels (ISVs) thanks to a controlled release of
both drugs, in a more effective way than NPs loaded with just one of the treatments [178].
Zebrafish models also offer advantages in terms of ethical and economic issues for the
screening of new treatments. After an initial in vitro selection of drugs from traditional
Chinese medicine to treat GBM stem cells, the 13 best candidates were evaluated for toxicity
and anti-tumoral efficacy in U87MG-zebrafish models, resulting in the selection of clofoctol
as the compound with the best activity ascribed to overexpression of a pro-apoptotic factor
(KLF13) [179].
Genetic and epigenetic therapies have been also tested using zebrafish GBM models.
Protein arginine methyltransferase 5 (PRMT5) inhibitors, which regulate gene expression by
methylation of histonic and non-histonic proteins, improved survival after microinjection
of GBM human derived cells expressing GFP in the midbrain-hindbrain of 36hpf casper
zebrafish [180]. Schnekenburger et al. synthetized and tested inhibitors of HDAC and
sirtuin (SIRT) in GBM-xenografts, showing their efficacy in preventing tumor growth [181].
An interesting pharmacological approach has been based on the following observation by
Pudelko et al.: human mutT homologue 1 (MTH1), an enzyme responsible for degrading
oxidized nucleotides—which have high oxidative pressure and protect tumor cells—is
up-regulated in GBM and related to a poor prognosis [184]. To treat this condition, MTH1
inhibitors, which force the cancer cell to incorporate oxidized nucleotides into the DNA,
have been tested in orthotopic GBM-zebrafish models, showing satisfactory anti-tumoral
efficacy. Tiek et al. studied in vitro the functions of the three isoforms of the estrogen-related
receptor β (ERR-β) in the context of GBM. By using a TMZ-resistant GBM cell line labeled
with DiL and microinjected into the brain of zebrafish, significant anti-tumoral activity was
revealed when an ERR-β agonist (DY131, which displaces the ERR-β towards the ERR-β2
isoform) was combined with a CLK inhibitor (TG-003) [182]. In another study, 5-fluorouracil
and erlotinib (tyrosin kinase inhibitor) reduced tumor size in zebrafish xenotransplants
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with murine-GBM-cells overexpressing ERR-β2 [183]. Thus, these treatments could be a
good alternative for TMZ-resistant tumors.
Zebrafish models have been applied to evaluate the outcomes of metabolic manip-
ulation in cancer progression and GBM [187]. Shtraizent et al. showed how mannose
phosphate isomerase, as a metabolic enzyme, can maintain Warburg metabolism in ze-
brafish embryos with GBM [188]. Using the same zebrafish tumor model, Wehmas et al.
observed significant tumor inhibition after treatment with LY294002, a selective PI3K in-
hibitor [167]. These results validate the same findings observed in organotypic mouse brain
tissues [189].
5.2. Use of Zebrafish to Test Anti-Angiogenic Activity
Inhibition of angiogenesis is applied for the treatment of cancer to reduce the supply
of oxygen and nutrients to the tumor, commonly in combination with other therapies [190].
Several zebrafish models have been used as tools for evaluating angiogenesis as well as
brain pathologies in real time [191,192]. An interesting protocol to study tumor angiogen-
esis using zebrafish embryos was established in 2007 [139] and advantages/limitations
of this model versus others have been reviewed by Nowak-Sliwinska et al. [193]. In the
context of GBM, Wang et al. tested natural inhibitors of cyclooxygenase-2 (COX-2), micro-
somal prostaglandin E synthase-1 (mPGES-1) and cytochrome P450 (CYP4A11) as enzymes
involved in angiogenic development [194]. Among different flavonoids, isoliquiritigenin
(ISL) showed the most potent anti-angiogenic activity in zebrafish and rabbit corneal mod-
els. This anti-angiogenic effect led to an improved anti-tumoral efficacy and normalized
glioma vasculature in combination with TMZ in murine models of glioma. In another
study, the chemotherapeutic agent dianhydrogalactitol (DAG) was evaluated in zebrafish
models for phase II clinical GBM trials where inhibition of migration and invasion of
glioma cells was seen as well as dose-dependent reduction in the expression of VEGF,
VEGFR2, FGF2 and FGFR2, all of which correlated with reduced tumor angiogenesis [195].
Bousseau et al. demonstrated the ability of a phosphite (PST3.1a) to block angiogenesis
by interaction with VEGFR2 and galectin-1 [196], using zebrafish. Nordy, an inhibitor
of arachinodate 5-lipoxygenase, was compared with well-known VEGF receptor tyrosin
kinase inhibitors (i.e., Vetalanib, Suntinib and Axitinib) in zebrafish embryos whose yolk
sacs had been injected with GSCs; the results showed how they were able to block tumor-
induced vessel formation and inhibit the invasion and proliferation of GSCs by promoting
their differentiation [186].
5.3. Use of Zebrafish to Test the Ability of Drugs to Cross the Blood–Brain–Barrier
A major limitation in the application of new drugs in the fight against GBM is their
ability to cross the Blood–brain–barrier (BBB). This physiological barrier limits the passage
of molecules from the circulatory system to the central nervous system (CNS) and is the
cause of failure for 98% of the drugs that target the CNSs tested in clinical trials [197].
Previous studies on the development and maturation of the BBB in zebrafish have
shown a sophisticated BBB, which is functionally and structurally similar to that of higher
vertebrates. Although it is not exactly the same, these studies suggest the use of zebrafish
as an experimental model organism for BBB-penetrating drug screenings [174,198]. Con-
sequently, several drug delivery systems have been tested with the aim of improving the
ability of pharmacological molecules to cross it. According to studies carried out on both
mammals and zebrafish, their similar BBBs have been attributed not only to the neurovas-
cular cellular composition, namely endothelial cells, pericytes, glia, neurons and microglia,
but also to their associations, tight junction proteins and active transport systems [199].
Likewise, high concordance has been reported in the development and function of CNS
capillaries and underlying molecular events driving these processes [192]. Additionally,
the expression of Claudin-5 and ZO-1, which is concomitant with the maturation of the
BBB, was detected in cerebral microvessels from 3 days dpf [174,198]. Nevertheless, several
issues have been encountered in certain studies. For instance, zebrafish present a popula-
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tion of radial glia instead of the classic stellate astrocytes in mammals and although this
glia expresses relevant astrocytic signals and also plays a role for ion homeostasis in the
brain, some differences which remain to be fully understood might be encountered [200].
Some differences between mammalian and zebrafish pericytes have been found, such as
lack of expression of canonical markers in the latter (i.e., Rgs5a or Desmin a/b) [201]. The
origin of cranial pericytes is exclusive to the neural crest in mammals, while in zebrafish
pericytes may also be of mesenchymal origin [202]. Despite these limitations, the flexibility,
predictability and translational value of rigorous experiments of zebrafish for humans
should be considered when using zebrafish BBB models for preclinical screenings of new
therapies. Below we provide some examples.
Doxorubicin (DOX), a chemotherapeutic commonly used in cancer and unable to
cross the BBB, is encapsulated in an apoferritin nanocage to target the transferrin receptor 1
(TfR1) overexpressed in brain endothelial cells and GBM cells. These NPs, labeled with the
fluorescent dye Cy5.5, upon injection in the hearts of zebrafish are able to cross the BBB,
so are an interesting strategy against GBM [197]. The same TfR1 ligand is used in carbon
nitride dots, conjugated with gemcitabine and transferrin (CN-GM-Tf) NPs, showing
strong anti-tumoral efficacy in GBM zebrafish models [203]. Another approach consists of
vincristine sulfate in powder form added to low-density lipoprotein (LDL, expressed in
the endothelial cells of the BBB and glioma cells) NPs modified with the T7 peptide TfR
ligand. This dual interaction is also effective in crossing the BBB and acting on GBM, but
using LDL nanocarriers could be problematic in patients with high cholesterol levels [204].
Zou et al. used monosialotetrahexosylganglioside (GM1) as a targeting ligand to improve
the transport of DOX-loaded micelles through the BBB [205]. LysoGM1, a product of GM1
hydrolysis with a hydrophilic group to improve the transport across the BBB, is used
to functionalize poly(lactic-co-glycolic acid) (PLGA) NPs loaded with DOX. DOX/GM1
and PLGA-lysoGM1/DOX are able to increase the anti-tumoral efficacy of DOX in GBM
zebrafish models and improve nerve functions [205,206].
5.4. Use of Zebrafish to Test the Toxicity of Drugs
In addition to the studies detailed above, zebrafish have been widely used for toxicity,
biocompatibility and/or biodistribution screening of drugs, benefiting from its ease of use
and ethical and economic advantages versus other animal models. For example, cobalt (III)
bound to nimesulide (Co-NMS), a COX-2 inhibitor, has been proven to increase the effects
of radiotherapy in GBM and its neurotoxicity has been evaluated in zebrafish models
from the changes in neurobehaviour capacity (swimming activity and movement) and
morphological abnormalities in the CNS from hematoxylin/eosin staining of histological
sections of the brain. Reduction in brain function and development has been observed at
Co-NMS concentrations higher than 10 µM, while 5 µM concentration has been consid-
ered to be safe; there has also been a more intense radiotherapy effect on GBM in terms
of a rise in the generation of ROSs and mitochondria damage in tumor cells [207]. Sev-
eral alkaloids (i.e., moschamine, N-p-coumaroyl serotonin) have been tested in zebrafish,
which showed no toxicity, although cytostatic and cytotoxic effects towards GBM cells
were induced [208,209]. Curcumin, a neuroprotective phytotherapeutic, encapsulated
in methoxy-poly(ethylene-glycol)-poly(ε-caprolactone) (MPEG-PCL) NPs showed better
absorption and biodistribution versus the free drug, in particular in lipophilic areas, such
as the CNS and the yolk sac [210].
As a whole, several studies using zebrafish have been performed for large drug
screenings and also to understand the mechanism of action of particular treatments in
zebrafish GBM. Furthermore, optimized zebrafish models, described in Section 4, offer
valuable tools for further studies, expected in the near future, on the effect of new drugs in
particular cases (i.e., genetic modifications) and the TME (i.e., macrophages).
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6. Conclusions
In recent years, seminal studies on glioblastoma (GBM) have unraveled the interac-
tions between tumor cells and immune cells from the initial steps and along the progression
of the pathology. In this regard, macrophages/microglia, representing up to 30-50% of
cells in some tumors, present protumoral properties and functions which can, in theory, be
reprogrammed with appropriate treatments, not yet available in the clinic, as suggested by
some pre-clinical results described in Section 2. In fact, 11 open phase III clinical trials for
GBM patients are ongoing, mostly related with immunotherapy [211]. Despite significant
scientific efforts, the standard of care treatment for GBM is still surgery, followed by ra-
diotherapy and TMZ, with only evaluation of IDH mutations and methylation of MGMT
as molecular markers of routine to classify and treat the disease. Numerous studies have
revealed genetic, epigenetic and metabolic alterations encountered in GBM. Among them,
we highlight the identification of miRNAs and their changes in GBM as very attractive
targets for diagnosis and/or therapeutic purposes, following a similar trend to other types
of cancer [59–61,212].
In this context, genetic and xenotransplant zebrafish models have been successfully
used to generate new knowledge about GBM pathology and some studies have been
initiated for screening of new treatments. While there is still some room for improvement
related to the modeling of the human immune system and optimization of orthotopic
models of GBM in zebrafish, satisfactory results have already been established for detailed
understanding of gene and metabolic alterations of the disease.
Overall, we expect that zebrafish models will be further exploited by taking into
account their biological, ethical and economic advantages for the screening and compre-
hensive evaluation of new drugs to ultimately improve the treatment of patients with
glioblastoma.
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VEGF Vascular endothelial growth factor
VEGFR2 Vascular endothelial growth factor receptor 2
WHO World Health Organization
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ZFNs Zinc-finger nucleases
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αvβ5 Integrin αvβ5
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